New York, United States, July 19, 2022 (GLOBE NEWSWIRE) -- Autoimmune disease (AD) is a non-communicable disease that revolves around losing normal immune homeostasis. This organism is responsible for producing an irregular response for its tissue cells. Furthermore, autoimmune diseases revolve around the activation of self-reactive T cells, autoantibodies, and inflammation. Typically, immune cells can identify alien objects such as bacteria and viruses and send out fighter cells to counter their presence. Autoimmune diseases compel the immune system to attack itself. Some autoimmune diseases attack only a certain type of organ.
Rising prevalence of chronic diseases coupled with increasing patient pool are fueling the market growth. Growing public attention and increasing autoimmune disease intensity among the elderly population to boost the autoimmune disease diagnostics market growth.
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/autoimmune-disease-diagnostics-market/request-sample
Key Insights
- The global autoimmune disease diagnostics market was valued at USD 4,253.29 million in 2021, and is anticipated to generate 8089.97 million by 2030 at a CAGR of 7.25% by 2030.
- The market is categorized into systemic autoimmune disease and localized autoimmune disease based on disease type. Localized autoimmune disease is predicted 5209.99 million by 2030 at a CAGR 7.05% during the forecast period.
- By diagnosis, the market is segmented into antinuclear antibody tests, autoantibody tests, complete blood count (CBC), c-reactive protein (CRP), urinalysis, and other tests. Auto antibody tests segment is expected to generate 2105.77 million by 2030 and grow at a CAGR of 7.60%.
- Geographically, the market is divided into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The market in North America is valued at 114.60 million by 2030 at a CAGR 7.12% during the forecast period. Asia-Pacific is anticipated to grow at a higher CAGR of 7.66% during the projected period (2022-2030).
Technological Advancements Leading to Significant Growth
The most common forms of autoimmune detected are Crohn’s, scleroderma, psoriasis, Type 1 diabetes, and lupus. Increased product launches and rising number of growth strategies implemented by prominent players will further push the market size. However, the latest technological leaps allow for simultaneous identification/measurement of various antibodies. Improvement of technologies such as antigen microarray and mass spectrometry for antibody profiling indicated a wide range of positive results for analytical sensitivity and reproducibility. Moreover, introduction of automated testing methods such as automated indirect immunofluorescence, automated monoplex immunoassays, and automated multiplex immunoassays will ease testing times.
Furthermore, increasing opportunities in the Asia Pacific regions are owing to untapped growth potential and a wide patient pool. Rising number of research studies are expected to present several opportunities for revenue generation among the dominant players in the market. Rising awareness is also among the factors fueling the market growth.
Report Scope
| Report Metric | Details |
| Market Size | 8.08 Billion by 2030 |
| CAGR | 7.17 % (2022-2030) |
| Historical Data | 2019-2020 |
| Base Year | 2021 |
| Forecast Period | 2022-2030 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Disease Type, Diagnosis |
| Geographies Covered | North America, Europe, Asia-Pacific, LAME and Rest of the World |
| Key Companies Profiled/Vendors | Abbott Laboratories ,Biomerieux SA ,Bio-rad Laboratories Inc ,PerkinElmer Inc. (Euroimmun AG) ,Hoffmann-la Roche Ltd ,Werfen Company (Inova Diagnostics Inc.) ,Myriad Genetics Inc ,Siemens Healthineers Inc ,Thermo Fisher Scientific Inc ,Trinity Biotech PLC |
| Key Market Opportunities | New Entrants and Novel Methods for Detecting Autoimmune Diagnostics to Present New Opportunities for Market |
| Key Market Drivers | Rising Public Awareness and Increasing Prevalence of Autoimmune Diseases to Surge Growth Technological Advancements to Aid in Registering a Substantial Market Growth Rate |
Buy Now Full Report @ https://straitsresearch.com/buy-now/autoimmune-disease-diagnostics-market
Impact of COVID-19
By April 2021, the WHO reported 141,057,106 cases of the ongoing pandemic. Recent studies indicated that in many patients suffering from COVID-19, destruction of β-cells was observed, surging the cases of type 1 diabetes. This led to a decent growth substitute for the autoimmune disease diagnostics market. Moreover, as countries-imposed lockdowns during the ongoing pandemic, trade practices were suspended globally.
Furthermore, travel restrictions on regional and global levels were enforced, leaving a majority of the population to resort to their homes.. As in-patient visits to hospitals, clinics, and laboratories decline, the market for autoimmune disease diagnostics faced a decline. As the pandemic runs its course, the market is expected to pick up the pace owing to ease in lockdown measures along with increasing movement capabilities among the general population.
List of Key Players
- Abbott Laboratories
- Biomerieux SA
- Bio-rad Laboratories Inc
- PerkinElmer Inc. (Euroimmun AG)
- Hoffmann-la Roche Ltd
- Werfen Company (Inova Diagnostics Inc.)
- Myriad Genetics Inc
- Siemens Healthineers Inc
- Thermo Fisher Scientific Inc
- Trinity Biotech PLC
Global Autoimmune Disease Diagnostics Market: Segmentation
By Disease Type
- Systemic Autoimmune Disease
- Rheumatoid Arthritis
- Psoriasis
- Systemic Lupus Erythematosus (SLE)
- Multiple Sclerosis
- Other Systemic Autoimmune Diseases
- Localized Autoimmune Disease
- Inflammatory Bowel Disease
- Type 1 Diabetes
- Thyroid
- Other Localized Autoimmune Diseases
By Diagnosis
- Antinuclear Antibody Tests
- Autoantibody Tests
- Complete Blood Count (CBC)
- C-reactive Protein (CRP)
- Urinalysis
- Other Tests
By Region
- North America
- Europe
- Asia-Pacific
- Middle East & Africa
- South America
TABLE OF CONTENT
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Executive Summary
4 Market Overview
4.1 Report Segmentation & Scope
4.2 Value Chain Analysis: Autoimmune Disease Diagnostics Market
4.2.1 Vendor Matrix
4.3 Key Market Trends
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Environment & Regulatory Landscape
4.6 Forecast Factors & Relevance of Impact
4.7 Macro-Economic & Geopolitical Scenario
4.8 Parent Market Overview
4.9 Technology Landscape
4.10 Market Share Analysis
4.11 Potential Venture Analysis
4.12 Regional Price Trends
4.13 Raw Material Trends
4.14 Cost Structure Analysis
4.14.1 Labor Cost
4.14.2 Consumables
4.14.3 Maintenance Cost
4.15 Covid-19 Impact Analysis:
4.15.1 Pre and Post Covid-19 Market Scenario Analysis
4.15.2 Market Recovery Timeline and Challenge
4.15.3 Measures Taken by Top Players
4.15.4 Quarterly Market Revenue and Growth Forecast till 2021
4.15.4.1 North America
4.15.4.2 Europe
4.15.4.3 Asia-Pacific
4.15.4.4 Central and South America and the Caribbean
4.15.4.5 The Middle East and Africa
5 Disease Type Overview
5.1 Introduction
5.1.1 Market Size & Forecast (Value & Volume)
5.2 Systemic Autoimmune Disease
5.2.1 Market Size & Forecast (Value & Volume)
5.3 Localized Autoimmune Disease
5.3.1 Market Size & Forecast (Value & Volume)
6 Diagnosis Overview
6.1 Introduction
6.1.1 Market Size & Forecast (Value & Volume)
6.2 Antinuclear Antibody Tests
6.2.1 Market Size & Forecast (Value & Volume)
6.3 Autoantibody Tests
6.3.1 Market Size & Forecast (Value & Volume)
6.4 Complete Blood Count (CBC)
6.4.1 Market Size & Forecast (Value & Volume)
6.5 C-reactive Protein (CRP)
6.5.1 Market Size & Forecast (Value & Volume)
6.6 Urinalysis
6.6.1 Market Size & Forecast (Value & Volume)
6.7 Other Tests
6.7.1 Market Size & Forecast (Value & Volume)
7 Regional Overview
7.1 Introduction
7.1.1 Market Size & Forecast (Value & Volume)
7.2 North America
7.2.1 Economic Overview
7.2.2 Market Scenario
7.2.3 U.S.
7.2.4 Canada
7.2.5 Mexico
7.3 Central and South America and the Caribbean
7.3.1 Economic Overview
7.3.2 Market Scenario
7.3.3 Brazil
7.3.4 Argentina
7.3.5 Colombia
7.3.6 Rest of Central and South America and the Caribbean
7.4 Europe
7.4.1 Economic Overview
7.4.2 Market Scenario
7.4.3 Germany
7.4.4 France
7.4.5 The U.K.
7.4.6 Italy
7.4.7 The Rest Of Europe
7.5 Asia-Pacific (APAC)
7.5.1 Economic Overview
7.5.2 Market Scenario
7.5.3 China
7.5.4 Japan
7.5.5 India
7.5.6 Australia
7.5.7 South Korea
7.5.8 Rest Of APAC
7.6 Middle East
7.6.1 Economic Overview
7.6.2 Market Scenario
7.6.3 South Arabia
7.6.4 The UAE
7.6.5 Qatar
7.6.6 Oman
7.6.7 Turkey
7.6.8 The Rest Of Middle East
7.7 Africa
7.7.1 Economic Overview
7.7.2 Market Scenario
7.7.3 Nigeria
7.7.4 South Africa
7.7.5 The Rest Of Africa
8 Competitive Landscape — Manufacturers & Suppliers
8.1 Competition Dashboard
8.2 Industry Structure
8.3 Abbott Laboratories
8.3.1 Business Overview
8.3.2 Financial Performance
8.3.3 Recent Developments
8.3.4 Portfolio
8.4 Biomerieux SA
8.5 Bio-rad Laboratories Inc
8.6 PerkinElmer Inc. (Euroimmun AG)
8.7 Hoffmann-la Roche Ltd
8.8 Werfen Company (Inova Diagnostics Inc.)
8.9 Myriad Genetics Inc
8.10 Siemens Healthineers Inc
8.11 Thermo Fisher Scientific Inc
8.12 Trinity Biotech PLC
9 Conclusion & Recommendation
10 Acronyms & Abbreviations
Table of Content and Figure @ https://straitsresearch.com/report/autoimmune-disease-diagnostics-market/toc
Market News
- In October 2021, Exagen Inc. announced that it launched AVISE CTD and AVISE Lupus, a contracted covered service with Inland Empire Health Plan (IEHP). It provides enhanced care to approx. 1.4 million members.
- In March 2021, Roche and GenMark Diagnostics entered into a definitive merger agreement for Roche to fully acquire GenMark at a price of USD 24.05 per share in an all-cash transaction.
- In February 2021, Myriad Genetics Inc. launched a new enhancement on its Vectra test report. The new test report provides an individualized estimate of a patient’s one-year risk of rapid radiographic progression (RP). The RP result in every report is personalized based on the patient’s age, gender, and adiposity.
- In January 2021, Exagen Inc. announced that all AVISE test offerings (SLE Monitor, CTD, APS, Lupus, MTX, SLE Prognostic, Vasculitis AAV, MTX, and HCQ) contracted in-network service with Tufts Medical Center.
- In January 2021, Thermo Fisher Scientific Inc. launched the Phadia 200, which enables new levels of flexibility and automation for laboratory testing facilities to aid in the diagnosis of allergy and autoimmunity conditions in Europe.
- In September 2020 the Canadian company, SQI Diagnostics Inc. announced the expansion of rapid diagnostic testing portfolio, which has been targeting organ transplant, autoimmune disease, and serological testing.
- In July 2020, BioMérieux SA acquired Invisible Sentinel, a United States-based company that specialized in food and beverage molecular testing.
- In June 2020, Abbott and Tandem Diabetes Care signed a partnership agreement to develop and commercialize integrated diabetes solutions.
- In March 2019, PerkinElmer, Inc., received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its EUROIMMUN Anti-TissueTransglutaminase (tTG) ELISA. The test system is designed in a way to help clinicians confirm or it can be used to exclude a celiac disease diagnosis.
Have a Look at the Related Research Report
Molecular Diagnostics Market: Information by Product & Service, Technology, Application, End User and Regional Outlook — Forecast Till 2026
TB Diagnostics Market: Information by Test Type (Nucleic Acid Testing), End-User (Hospitals and Diagnostics Laboratories, Physician’s Office Laboratories), and Region — Forecast till 2030
B Cell Lymphoma Treatment Market: Information by Therapy (Immunotherapy, Targeted Therapy, Stem Cell Therapy), Route of Administration, End Users, and Region — Forecast till 2029
About Straits Research Pvt. Ltd.
StraitsResearch is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
Phone: +1 646 480 7505 (the U.S.)
+91 8087085354 (APAC)
+44 208 068 9665 (the U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter
